233 results for "Masellis, Mario"
Showing 1–20 · 0.68 seconds · RSS
-
Journal Article Full text
Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes
Parkinson's disease (PD) and atypical Parkinsonian syndromes are progressive heterogeneous neurodegenerative diseases that share clinical characteristic of parkinsonism as a common feature, but are considered distinct clinicopathological disorders. Based on the predominant protein aggregates…
-
Journal Article Full text
Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians
Fluid biomarkers improve the diagnostic accuracy in dementia and provide an objective measure potentially useful as a therapeutic response in clinical trials. The role of fluid biomarkers in patient care is a rapidly evolving field. Here, we provide a review and recommendations regarding the use of…
-
Journal Article Full text
A Multimodal Risk Network Predicts Executive Function Trajectories in Non-demented Aging
Background: Multiple modalities of Alzheimer’s disease (AD) risk factors may operate through interacting networks to predict differential cognitive trajectories in asymptomatic aging. We test such a network in a series of three analytic steps. First, we test independent associations between three…
-
Journal Article Full text
Brain atrophy trajectories predict differential functional performance in Alzheimer's disease: Moderations with apolipoprotein E and sex
INTRODUCTION: We examine whether distinct brain atrophy patterns (using brain parenchymal fraction [BPF]) differentially predict functional performance and decline in Alzheimer's disease (AD), and are independently moderated by (1) a key AD genetic risk marker (apolipoprotein E [APOE]), (2) sex…
-
Journal Article Full text
Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story
This review provides an update on the current state of pharmacogenetic research in the treatment of Alzheimer's disease (AD) and Lewy body disease (LBD) as it pertains to the use of cholinesterase inhibitors (ChEI). AD and LBD are first reviewed from clinical and pathophysiological perspectives…
Also available at: DOAJ
-
Journal Article Full text
Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome
With increasing knowledge of clinical in vivo biomarkers and the pathological intricacies of Alzheimer's disease (AD), nosology is evolving. Harmonized consensus criteria that emphasize prototypic illness continue to develop to achieve diagnostic clarity for treatment decisions and clinical trials…
-
Journal Article Full text
Clinical dementia severity associated with ventricular size is differentially moderated by cognitive reserve in men and women
BACKGROUND: Interindividual differences in cognitive reserve (CR) are associated with complex and dynamic clinical phenotypes observed in cognitive impairment and dementia. We tested whether (1) CR early in life (E-CR; measured by education and IQ), (2) CR later in life (L-CR; measured by…
-
Journal Article Full text
Rhombencephalitis in an 86-year-old woman with chronic lymphocytic leukemia
-
Journal Article Full text
Rhombencéphalite chez une femme de 86 ans atteinte de leucémie lymphoïde chronique
-
Journal Article Full text
The Opinions, Attitudes, and Practices of Physicians Regarding Pharmacologic Therapies for Dementia in Canada
BACKGROUND: Despite the approval of disease‐modifying therapies (DMTs) in select countries worldwide, cholinesterase inhibitors (ChEIs) and the NMDA receptor antagonist memantine remain the only approved pharmacologic agents for symptomatic treatment of dementia in Canada. The absence of…
-
Journal Article Full text
Absence of Linkage for Schizophrenia on the Short Arm of Chromosome 5 in Multiplex Canadian Families
A VNTR for the human dopamine transporter gene (DAT-1) has been localized to chromosome 5p15.3. Silverman et al. [1996] found evidence for genetic linkage of the D5S111 locus, located just centromeric to DAT-1, to schizophrenia and related disorders in a large Hispanic family. We evaluated five…
-
Journal Article Full text
The Return of Biomarker Results in Research: Balancing Complexity, Precision, and Ethical Responsibility
Recent research aimed at the discovery, integration, and communication of health outcome measures (or “biomarkers”) in Alzheimer’s disease has raised challenging questions related to whether, how and when results from these investigations should be disclosed to research participants. Reflecting the…
-
Journal Article Full text
Safety, Efficacy and Clinical Applications of Focused Ultrasound-Mediated Blood Brain Barrier Opening in Alzheimer's Disease: A Systematic Review
Alzheimer's disease is a neurodegenerative disorder marked by cognitive decline and brain pathology involving amyloid plaques and neurofibrillary tangles. Current drug development focuses on disease-modifying therapies, primarily antibodies targeting amyloid or tau. However, the blood-brain barrier…
-
Journal Article Full text
Integrating polygenic risk scores, modifiable dementia risk factors, and sex as predictors of cohort membership in the Alzheimer’s and Lewy body disease spectra: A COMPASS‐ND Study
BACKGROUND: Polygenic risk scores (PRSs) summarize genetic risk across single nucleotide polymorphisms (SNPs). Alzheimer’s disease (AD) and Lewy body disease (LBD) PRSs contribute to risk detection via both multi‐mechanism (SNPs from multiple mechanistic pathways) and mechanism‐specific (SNPs from…